Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor

Journal of Cancer Research and Therapeutics

Volumn 8, Issue 2, 2012, Pages 232-237

  Krishna, A ^a   Kaveri, H ^b   Naveen Kumar, R K ^c   Kumaraswamy, K L ^d   Shylaja, S ^a   Murthy, Sarvani ^c  

^a SVS Institute of Dental Sciences   (India)

^b SDM COLLEGE OF DENTAL SCIENCES AND HOSPITAL   (India)

^c Sri Hasanamba Dental College and Hospital   (India)

^d Farooqia Dental College and Hospital   (India)

Author keywords

Adenomatoid odontogenic tumor; ameloblastoma; immunohistochemistry; MDM2; odontogenic tumors

Indexed keywords

PROTEIN MDM2;

ADENOMATOID ODONTOGENIC TUMOR; AMELOBLASTOMA; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ODONTOGENIC TUMOR; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

AMELOBLASTOMA; CELL NUCLEUS; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; JAW NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MDM2; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84864679308     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.98976     Document Type: Article

References (17)

1. Weinberg RA. Oncogenes and tumor suppressor genes. CA Cancer J Clin 1994;44:160-70.
2. Saucedo LJ, Myers CD, Perry ME. Multiple murine double minute gene 2 (MDM2) proteins are induced by ultraviolet light. J Biol Che 1999;274:8161-8.
3. Onel K, Cardo CC. MDM2 and prognosis. Mol Cancer Res 2004;2:1-8.
4. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: Expression, clinical pathology, prognostic markers and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41.
5. Barnes L, Eveson JW, Reichart PA, Sidransky D. World Health Organization classification of tumor series. In: Pathology and genetics of head and neck. Lyon: IARC; 2005.
6. Dodds AP, Cannon RE, Suggs CA, Wright JT. mRNA expression and phenotype of odontogenic tumors in the v-Ha-ras transgenic mouse. Arch Oral Biol 2003;48:843-50.
7. Gomes CC, Alessandra PD, Marina GD, Ricardo SG. Current concepts of ameloblastoma pathogenesis. J Oral Pathol Med 2010;39:585-91.
8. Sandra F, Nakamura N, Kanematsu T, Hirata M, Ohishi M. The role of MDM2 in the proliferative activity of ameloblastomas. Oral Oncol 2002;38:153-7.
9. Kumamoto H, Izutsu T, Ohki K, Takahashi N, Ooya K. p53 gene status and expression of p53, MDM2 and p14ARF proteins in ameloblastomas. J Oral Pathol Med 2004;33:292-9.
10. Carvalhais J, Aguiar M, Araujo V, Araujo N, Gomez R. p53 and MDM2 expression in odontogenic cysts and tumors. Oral Dis 1999;5:218-22.
11. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
12. Asslaber D, Pinon JD, Seyfried J, Desch P, Stocher M, Tinhofer I, et al. microRNA-34a expression correlates with MDM2 SNP 309 polymorphism and treatment free survival in chronic lymphocytic leukemia. Blood 2010;115:4191-7.
13. Bose I, Ghosh B. The p53-MDM2 network: From oscillations to apoptosis. J Biosci 2007;32:991
14. Zhang R, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000;6:393-416.
15. Meer S, Galpin JS, Altini M, Coleman H, Ali H. Proliferating cell nuclear antigen and Ki-67 immunoreactivity in ameloblastomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:213-21.
16. Kumamoto H, Kimi K, Ooya K. Immunohistochemical analysis of apoptosis-related factors (Fas, Fas Ligand, Caspase 3 and single stranded DNA) in ameloblastomas. J Oral Pathol Med 2001;30:596-602.
17. Courtney RM, Kerr DA. The odontogenic adenomatoid tumor. A comprehensive study of twenty new cases. Oral Surg Oral Med Oral Pathol 1975;39:424-35.